Effective symptom relief with a smile
Dr. Cocoa® products contain trusted, effective ingredients: dextromethorphan, phenylephrine, and diphenhydramine.
Dr. Cocoa blends these active ingredients with 10% real cocoa for a real chocolate taste that children will not reject. Medicine palatability is important to successful dosing and compliance.
The effectiveness of the Dr. Cocoa Cough + Cold Nighttime liquid formula (diphenhydramine, phenylephrine) was demonstrated in a recent cough challenge study conducted among adults. The Dr. Cocoa formula demonstrated a significant suppression of the cough reflex versus placebo.1
These findings have been accepted for publication in the International Journal of Clinical Pharmacy. They were also presented at the 2014 European Respiratory Society International Congress, and later shared with doctors at the 2014 American Academy of Pediatrics Congress.
This is the first-ever study to demonstrate the ability of diphenhydramine to inhibit cough reflex sensitivity in adults with acute viral respiratory tract infection (common cold).
Palatability improves compliance
Medication compliance among children is an on-going issue. According to a study published in the American Academy of Pediatrics journal, medication compliance among children is only 50%2. Left untreated or undertreated, pediatric cough and cold symptoms can linger, putting a child at risk for the condition to worsen3. For example, an NIH funded study has demonstrated a clear link between cold viruses and ear infections (Otitis Media) in small children4. Palatability can play an important role in compliance in children5.
Dr. Cocoa has clinically demonstrated palatability
A clinical palatability study among 50 pediatric patients showed that on average the taste of Dr. Cocoa was rated as good.
Taste rated on a 5-point scale [1= really bad, 2=bad, 3=not sure, 4=good, 5=really good]. Dr. Cocoa achieved a mean rating of 4.14.
Pediatric Taste Study (2013); conducted among 50 patients, ages 6-12; 8-hour cough formulation tested. [Clinical Study Administrators: Radian Research, Pinellas Park, FL; Methodology: “The Standard Guide for Sensory Evaluations of Products by Children”; ASTM Designation: E2299-11]
1. Dicpinigaitis PV, Dhar S, Johnson A, Gayle Y, Brew J, Caparros-Wanderley W. Inhibition of cough reflex sensitivity by diphenhydramine during acute viral respiratory tract infection.Int J Clin Pharm 2015, in press. Study funded by a grant from infirst Healthcare Ltd. Study results provide the initial evidence of the ability of diphenhydramine to inhibit cough reflex sensitivity in subjects with acute pathological cough. 2.Winnick S., Lucas D.O., Hartman A.L., Toll D., (2005) How do you improve compliance?, Pediatrics p115
3. Dawood O.T., Ibrahim M.I.M., Palaian S., (2010) Medication compliance among children. World journal of pediatrics, Vol. 6, No. 3
4. Science Daily, March 14, 2008; available at sciencedaily.com
5. Wandstrat T.L., Kaplan B., (1997) Pharmacoeconomic impact of factors affecting compliance with antibiotic regimens in the treatment of acute otitis media. Pediatr Infect Dis J., 16 (suppl) s-27-s29
infirst Healthcare supports the efforts of StopMedicineAbuse.org to curb teen medicine abuse.